Wyeth Reports Earnings Results for the 2007 Fourth Quarter and... (the 2007 full year. Thesecharges include...)

Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year

Date:1/31/2008

the 2007 full year. These charges include costs pertaining to the closure of a manufacturing facility owned by Amgen Inc. and used in the production of Enbrel. The closure of the manufacturing facility was completed in the 2007 fourth quarter. The 2006 fourth quarter and full year included productivity initiatives charges of $63.8 million ($48.1 million after-tax or $0.03 per share-diluted) and $218.6 million ($154.5 million after-tax or $0.11 per share-diluted), respectively.

To assist in performing fourth quarter and full year comparisons, a pro forma presentation, which excludes our productivity initiatives and favorable income tax adjustment, is provided under "Results of Operations -- As Adjusted" at the end of this press release.

Segment Information

The following table sets forth worldwide net revenue by reportable segment together with the percentage changes from the comparable period in the prior year:

(UNAUDITED)

Three Months Ended Full Year Ended

12/31/2007 12/31/2007

Net Revenue By

Reportable Segment ($ in millions) Increase ($ in millions) Increase

Pharmaceuticals $4,724 10% $18,622 10%

Consumer Healthcare 787 10% 2,736 8%

Animal Health 253 24% 1,042 11%

Consolidated Total $5,764 10% $22,400 10%

Pharmaceuticals

Worldwide Pharmaceuticals net revenue increased 10% for the 2007 fourth quarter and full year due primarily to higher sales of Enbrel, Prevnar, Nutrition products, Zosyn(R), Protonix and Effexor. The increase in Pharmaceuticals net revenue was offset, in part, by lower sales of Inderal(R) LA due to generic competition. Alliance revenue decreased 13% to $321 million for the 2007 fourth quarter and decreas
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related biology technology :

1. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
2. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
3. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
4. Wyeth Announces Election of New Principal Corporate Officer
5. Wyeth Declares Preferred Stock Dividend
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
8. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound

Post Your Comments:

Wyeth Reports Earnings Results for the 2007 Fourth Quarter and...(the 2007 full year. Thesecharges include...)